[1] World Health Organization, 2021. Global Tuberculosis Report. Available from: https://www.who.int/publications/i/item/9789240037021. [2021-10-14].
[2] Viney K, Linh NN, Gegia M, et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. Eur Respir J, 2021; 57, 2100361. doi:  10.1183/13993003.00361-2021
[3] Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother, 2012; 67, 819−31. doi:  10.1093/jac/dkr566
[4] Kabir S, Tahir Z, Mukhtar N, et al. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. BMC Pulm Med, 2020; 20, 1−6. doi:  10.1186/s12890-019-1042-0
[5] Walker TM, Miotto P, Köser CU, et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis. Lancet Microbe, 2022; 3, e265−e273. doi:  10.1016/S2666-5247(21)00301-3
[6] Dunbar SA. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta, 2006; 363, 71−82. doi:  10.1016/j.cccn.2005.06.023
[7] Ou X, Zhang Z, Zhao B, et al. Evaluation study of xMAP TIER assay on a microsphere-based platform for detecting first-Line anti-tuberculosis drug resistance. Int J Environ Res Public Health, 2022; 19, 17068. doi:  10.3390/ijerph192417068
[8] Freschi L, Vargas R Jr, Husain A, et al. Population structure, biogeography and transmissibility of Mycobacterium tuberculosis. Nat Commun, 2021; 12, 6099. doi:  10.1038/s41467-021-26248-1
[9] Eilertson B, Maruri F, Blackman A, et al. High proportion of heteroresistance in GyrA and GyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother, 2014; 58, 3270−5. doi:  10.1128/AAC.02066-13
[10] Pantel A, Petrella S, Veziris N, et al. Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis. J Antimicrob Chemother, 2016; 71, 2428−31. doi:  10.1093/jac/dkw169